Glucagon receptor/GLP-1 receptor dual agonists

1. Glucagon receptor/GLP-1 receptor dual agonists decrease hepatic fibrosis in humans.

   “In early clinical trials, some dual agonists substantially reduced body weight, hepatic steatosis, and hepatic fibrosis.”

   ReviewEarly clinical trials of some dual agonistsliver

   The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus

   Obesity reviews : an official journal of the International Association for the Study of Obesity·11 Oct 2026

More on Hepatic fibrosis

1. Glucagon receptor/GLP-1 receptor dual agonists decrease hepatic steatosis in humans.

   “In early clinical trials, some dual agonists substantially reduced body weight, hepatic steatosis, and hepatic fibrosis.”

   ReviewEarly clinical trials of some dual agonistsliver

   The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus

   Obesity reviews : an official journal of the International Association for the Study of Obesity·11 Oct 2026

More on Hepatic steatosis

1. Glucagon receptor/GLP-1 receptor dual agonists decrease body weight in humans.

   “In early clinical trials, some dual agonists substantially reduced body weight, hepatic steatosis, and hepatic fibrosis.”

   ReviewEarly clinical trials of some dual agonists

   The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus

   Obesity reviews : an official journal of the International Association for the Study of Obesity·11 Oct 2026